Shu Li
About
In The Last Decade
Shu Li
44 papers receiving 9.1k citations
Hit Papers
Peers
Comparison fields: 5 of 92
- Immunology 8.2k
- Dermatology 4.2k
- Rheumatology 2.5k
- Hematology 1.8k
- Pathology and Forensic Medicine 1.3k
Countries citing papers authored by Shu Li
This map shows the geographic impact of Shu Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shu Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shu Li more than expected).
Fields of papers citing papers by Shu Li
This network shows the impact of papers produced by Shu Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shu Li. The network helps show where Shu Li may publish in the future.
Co-authorship network of co-authors of Shu Li
This figure shows the co-authorship network connecting the top 25 collaborators of Shu Li. A scholar is included among the top collaborators of Shu Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shu Li. Shu Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 0 | |
| 3 | 31 | |
| 4 | 5 | |
| 5 | 3 | |
| 6 | 76 | |
| 7 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial breakdown → | 637 |
| 8 | Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial breakdown → | 537 |
| 9 | 166 | |
| 10 | 242 | |
| 11 | Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial breakdown → | 508 |
| 12 | Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial breakdown → | 606 |
| 13 | 110 | |
| 14 | 82 | |
| 15 | 446 | |
| 16 | 121 | |
| 17 | 31 | |
| 18 | Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial breakdown → | 838 |
| 19 | Şiddetli plak tipi psoriazisde infliksimab indüksiyon tedavisi: Randomize, çift-kör, plasebo kontrollü çalışma | 1 |
| 20 | 456 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.